CN101932586A - 蛋白酪氨酸激酶活性的抑制 - Google Patents

蛋白酪氨酸激酶活性的抑制 Download PDF

Info

Publication number
CN101932586A
CN101932586A CN2008801139404A CN200880113940A CN101932586A CN 101932586 A CN101932586 A CN 101932586A CN 2008801139404 A CN2008801139404 A CN 2008801139404A CN 200880113940 A CN200880113940 A CN 200880113940A CN 101932586 A CN101932586 A CN 101932586A
Authority
CN
China
Prior art keywords
alkyl
optional
group
aryl
unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801139404A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·W·克拉里奇
朱波米尔·伊萨科维克
迈克尔·曼尼恩
斯蒂芬·雷佩尔
奥斯卡·M·萨维德拉
弗雷德里克·高德特
战莉洁
南希·Z·周
弗兰克·雷佩尔
罗伯特·德齐尔
阿卡迪·瓦斯伯格
宇野哲之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
7503547 Canada Co
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Priority to CN201910332646.2A priority Critical patent/CN109970759A/zh
Priority to CN201610143388.XA priority patent/CN105777776B/zh
Publication of CN101932586A publication Critical patent/CN101932586A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2008801139404A 2007-08-29 2008-08-28 蛋白酪氨酸激酶活性的抑制 Pending CN101932586A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910332646.2A CN109970759A (zh) 2007-08-29 2008-08-28 蛋白酪氨酸激酶活性的抑制剂
CN201610143388.XA CN105777776B (zh) 2007-08-29 2008-08-28 蛋白酪氨酸激酶活性的抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96867307P 2007-08-29 2007-08-29
US60/968,673 2007-08-29
PCT/CA2008/001538 WO2009026717A1 (en) 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201610143388.XA Division CN105777776B (zh) 2007-08-29 2008-08-28 蛋白酪氨酸激酶活性的抑制剂
CN201910332646.2A Division CN109970759A (zh) 2007-08-29 2008-08-28 蛋白酪氨酸激酶活性的抑制剂

Publications (1)

Publication Number Publication Date
CN101932586A true CN101932586A (zh) 2010-12-29

Family

ID=40386626

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2008801139404A Pending CN101932586A (zh) 2007-08-29 2008-08-28 蛋白酪氨酸激酶活性的抑制
CN201910332646.2A Pending CN109970759A (zh) 2007-08-29 2008-08-28 蛋白酪氨酸激酶活性的抑制剂
CN201610143388.XA Active CN105777776B (zh) 2007-08-29 2008-08-28 蛋白酪氨酸激酶活性的抑制剂

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910332646.2A Pending CN109970759A (zh) 2007-08-29 2008-08-28 蛋白酪氨酸激酶活性的抑制剂
CN201610143388.XA Active CN105777776B (zh) 2007-08-29 2008-08-28 蛋白酪氨酸激酶活性的抑制剂

Country Status (19)

Country Link
US (3) US8404846B2 (enExample)
EP (1) EP2183254B1 (enExample)
JP (1) JP5656634B2 (enExample)
KR (1) KR101556269B1 (enExample)
CN (3) CN101932586A (enExample)
AR (1) AR068066A1 (enExample)
AU (1) AU2008293038B2 (enExample)
BR (1) BRPI0816064B8 (enExample)
CA (1) CA2697795C (enExample)
DK (1) DK2183254T3 (enExample)
ES (1) ES2635131T3 (enExample)
IL (1) IL204192A (enExample)
MX (1) MX2010002427A (enExample)
MY (1) MY156536A (enExample)
PL (1) PL2183254T3 (enExample)
RU (1) RU2495044C2 (enExample)
TW (1) TWI571468B (enExample)
WO (1) WO2009026717A1 (enExample)
ZA (1) ZA201001512B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
WO2014029250A1 (zh) * 2012-08-24 2014-02-27 辰欣药业股份有限公司 苯并吡啶氮杂卓类化合物及其应用
CN111295386A (zh) * 2018-03-08 2020-06-16 伟迈可生物有限公司 噻吩并吡啶衍生物及含有该衍生物的药物组合物
CN114401720A (zh) * 2019-09-10 2022-04-26 米拉蒂治疗股份有限公司 多酪氨酸激酶抑制剂的晶型、制备方法及其用途
WO2023155777A1 (en) * 2022-02-15 2023-08-24 Beigene (Suzhou) Co., Ltd. N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof
CN116963734A (zh) * 2021-03-10 2023-10-27 米拉蒂治疗股份有限公司 多重酪胺酸激酶抑制剂的结晶盐、其制备方法及用途

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923670A2 (pt) * 2008-03-05 2013-07-30 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase e seu uso, bem como composiÇço compreendendo os mesmos
WO2010045095A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
CA2752421C (en) * 2009-03-21 2013-08-06 Ning Xi Amino ester derivatives, salts thereof and methods of use
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
JP5868855B2 (ja) * 2009-09-03 2016-02-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ チロシンキナーゼ調節剤としての化合物
MY157319A (en) * 2010-04-16 2016-05-31 Methylgene Inc Inhibitors of protein tyrosine kinase activity
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
JP6158705B2 (ja) * 2010-09-27 2017-07-05 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
CA2812744A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP2621482A1 (en) * 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CA2969540C (en) 2014-12-02 2023-03-21 Ignyta, Inc. Combinations for the treatment of neuroblastoma
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
CA3100766A1 (en) 2018-05-23 2019-11-28 Beigene, Ltd. Anti-ox40 antibodies and methods of use
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物
US20230172914A1 (en) 2019-09-06 2023-06-08 Wellmarker Bio Co., Ltd. Biomarker-based therapeutic composition
US20230022859A1 (en) * 2019-11-21 2023-01-26 Beigene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
CN114945576B (zh) * 2020-01-07 2023-10-13 南京明德新药研发有限公司 氘代噻吩并吡啶类化合物
EP4213844A4 (en) 2020-09-17 2024-11-20 Mirati Therapeutics, Inc. POLYTHERAPIES
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004675A1 (en) * 2005-05-20 2007-01-04 Methylgene, Inc. Inhibitors of VEGF receptor and HGF receptor signaling

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7000A (en) * 1850-01-08 Smut-machine
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
BRPI0209216B8 (pt) 2001-04-27 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
CA2468989A1 (en) * 2001-12-07 2003-06-19 Daniel M. Schwartz Treatment for age-related macular degeneration
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
ES2436888T3 (es) 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
CN1906167A (zh) 2004-02-27 2007-01-31 卫材株式会社 新型吡啶衍生物及嘧啶衍生物(2)
US8940896B2 (en) * 2004-03-15 2015-01-27 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006010264A1 (en) * 2004-07-30 2006-02-02 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1904504B1 (en) * 2005-05-20 2014-03-19 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
BRPI0616799B8 (pt) 2005-08-24 2021-05-25 Eisai R&D Man Co Ltd derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor
TW200806675A (en) * 2006-01-30 2008-02-01 Array Biopharma Inc Heterobicyclic thiophene compounds and methods of use
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
JP2009539878A (ja) 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
JP2010507618A (ja) 2006-10-27 2010-03-11 グラクソ グループ リミテッド ｃ−Ｍｅｔキナーゼ阻害薬としての７−アザインドール誘導体
MY157319A (en) * 2010-04-16 2016-05-31 Methylgene Inc Inhibitors of protein tyrosine kinase activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004675A1 (en) * 2005-05-20 2007-01-04 Methylgene, Inc. Inhibitors of VEGF receptor and HGF receptor signaling

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
WO2014029250A1 (zh) * 2012-08-24 2014-02-27 辰欣药业股份有限公司 苯并吡啶氮杂卓类化合物及其应用
CN111295386A (zh) * 2018-03-08 2020-06-16 伟迈可生物有限公司 噻吩并吡啶衍生物及含有该衍生物的药物组合物
CN114401720A (zh) * 2019-09-10 2022-04-26 米拉蒂治疗股份有限公司 多酪氨酸激酶抑制剂的晶型、制备方法及其用途
CN116963734A (zh) * 2021-03-10 2023-10-27 米拉蒂治疗股份有限公司 多重酪胺酸激酶抑制剂的结晶盐、其制备方法及用途
WO2023155777A1 (en) * 2022-02-15 2023-08-24 Beigene (Suzhou) Co., Ltd. N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof

Also Published As

Publication number Publication date
DK2183254T3 (en) 2017-09-11
EP2183254B1 (en) 2017-06-21
EP2183254A1 (en) 2010-05-12
EP2183254A4 (en) 2011-09-28
AR068066A1 (es) 2009-11-04
US20130165477A1 (en) 2013-06-27
TWI571468B (zh) 2017-02-21
CA2697795A1 (en) 2009-03-05
AU2008293038A1 (en) 2009-03-05
JP2010536887A (ja) 2010-12-02
ES2635131T3 (es) 2017-10-02
AU2008293038B2 (en) 2013-08-29
MX2010002427A (es) 2010-03-30
WO2009026717A1 (en) 2009-03-05
BRPI0816064A2 (pt) 2015-03-31
US20090264440A1 (en) 2009-10-22
US8846927B2 (en) 2014-09-30
CA2697795C (en) 2016-08-16
TW200914458A (en) 2009-04-01
CN105777776A (zh) 2016-07-20
RU2495044C2 (ru) 2013-10-10
JP5656634B2 (ja) 2015-01-21
CN105777776B (zh) 2021-06-08
US20120108628A1 (en) 2012-05-03
MY156536A (en) 2016-02-26
US8389541B2 (en) 2013-03-05
RU2010111729A (ru) 2011-10-10
CN109970759A (zh) 2019-07-05
KR101556269B1 (ko) 2015-09-30
BRPI0816064B1 (pt) 2020-01-28
IL204192A (en) 2016-08-31
KR20100075873A (ko) 2010-07-05
BRPI0816064B8 (pt) 2021-05-25
ZA201001512B (en) 2010-11-24
US8404846B2 (en) 2013-03-26
PL2183254T3 (pl) 2017-10-31

Similar Documents

Publication Publication Date Title
CN105777776B (zh) 蛋白酪氨酸激酶活性的抑制剂
CN102015723B (zh) 蛋白酪氨酸激酶活性的抑制剂
CN101796055B (zh) Vegf受体和hgf受体信号的抑制剂
JP2013525286A (ja) タンパク質チロシンキナーゼ活性の阻害剤
TW201329085A (zh) 蛋白酪氨酸激酶活性抑制劑
TW201329086A (zh) 蛋白酪氨酸激酶活性抑制劑
HK1139407B (en) Inhibitors of protein tyrosine kinase activity
HK1139407A (en) Inhibitors of protein tyrosine kinase activity
HK1155977A (en) Inhibitors of protein tyrosine kinase activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CANADA CO., LTD., 7503547

Free format text: FORMER OWNER: 9222-9129 QUEBEC INC.

Effective date: 20110111

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20110111

Address after: Quebec

Applicant after: 7503547 Canada Company

Address before: Quebec

Applicant before: 9222-9129 Quebec Corporation

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101229